Sidley advised KKR on its majority acquisition of Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company headquartered in Switzerland, with further operations in the UK, the U.S., Slovakia, and China. Biosynth Carbosynth supplies products to players across the pharmaceutical, life sciences, food, agrochemical, cosmetic and diagnostic sectors, and manufactures and sources a range of chemical and biochemical products.
The Sidley team in Europe was led by Private Equity partners Wim De Vlieger and Till Lefranc, supported by associates Jakob Egle, Hui Zhen Gan, Tom Johnson, and Jessica Edwards. Additional support was provided by European partners Patrick Harrison, Maria Isabel Manley, Maurits J.F. Lugard, Sven De Knop, Jade Williams-Adedeji, James Crooks, Susan Fanning, and Oliver Currall; senior advisor Andreas Balsiger Betts; counsel Rosanna Connolly, Olivier Goarnisson, and Helen Middleton; senior associates Isabel Berger, Jonathan Lafferty, Josefine Sommer, Jack Mayall, Jo Bainton, and Francesca Blythe; associates Mia Gal, Zina Chatzidimitriadou, Alessandra Moroni, Maryanne Kamau, Nils Gravenhorst, Michael Condlyffe, Alex Down, and Nicole Bieber. The team in the U.S. included counsel Edward Sharon and associate Andy Lau.